Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | CAPN1 | P07384 | 8/20 | 0.43 |
| ▸ | CTSK | P43235 | 2/20 | 0.42 |
| ▸ | CTSB | P07858 | 5/20 | 0.38 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7974645 | 1.00 | ALDH1A1 (0.50) | ALDH1A1CAPN1CTSKCTSBKISS1R | |
| SCHEMBL12219762 | 1.00 | ALDH1A1 (0.50) | ALDH1A1CAPN1CTSKCTSBKISS1R | |
| SCHEMBL7911546 | 0.89 | ALDH1A1 (0.42) | ALDH1A1CAPN1CTSKCTSB | |
| SCHEMBL5493312 | 0.85 | ALDH1A1 (0.55) | ALDH1A1CAPN1CTSKCTSB | |
| SCHEMBL5493308 | 0.85 | ALDH1A1 (0.55) | ALDH1A1CAPN1CTSKCTSB | |
| SCHEMBL7510270 | 0.84 | ALDH1A1 (0.53) | ALDH1A1CAPN1CTSB | |
| SCHEMBL9542347 | 0.84 | ALDH1A1 (0.53) | ALDH1A1CAPN1CTSB | |
| SCHEMBL3866137 | 0.84 | ALDH1A1 (0.53) | ALDH1A1CAPN1CTSB | |
| SCHEMBL28305778 | 0.83 | ALDH1A1 (0.38) | ALDH1A1CAPN1CTSK | |
| SCHEMBL3332680 | 0.83 | CAPN1 (0.47) | ALDH1A1CAPN1CTSKCTSBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020173469-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-11-21 | — | — | US | claimed |
| US-20020077455-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-06-20 | — | — | US | claimed |
| US-6284777-B1 | BONE DISORDERS | SMITHKLINE BEECHAM CORPORATION | 2001-09-04 | — | — | US | claimed |
| EP-0934291-A4 | — | SMITHKLINE BEECHAM CORP (US) | 1999-08-11 | — | — | EP | claimed |
| EP-0934291-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-08-11 | — | — | EP | claimed |
| WO-1997016433-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-05-09 | — | — | WO | claimed |
| US-10435756-B2 | Selective inhibitors of tumor-initiating cells | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2019-10-08 | — | — | US | disclosed |
| US-20180105883-A1 | SELECTIVE INHIBITORS OF TUMOR-INITIATING CELLS | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2018-04-19 | — | — | US | disclosed |
| US-9689040-B2 | Selective inhibitors of tumor-initiating cells | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2017-06-27 | — | — | US | disclosed |
| US-20170114098-A1 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | AILERON THERAPEUTICS, INC. | 2017-04-27 | — | — | US | disclosed |
| US-9505804-B2 | Peptidomimetic macrocycles | AILERON THERAPEUTICS, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-20160333049-A1 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | AILERON THERAPEUTICS, INC. | 2016-11-17 | — | — | US | disclosed |
| WO-2016154058-A1 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | AILERON THERAPEUTICS, INC. (US) | 2016-09-29 | — | — | WO | disclosed |
| WO-1997016433-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-05-09 | — | — | WO | disclosed |
| EP-0696208-A4 | ORAL DRUG DELIVERY COMPOSITIONS AND METHODS | EMISPHERE TECH INC (US) | 1997-01-29 | — | — | EP | disclosed |
| WO-1996039142-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A PROTEINASE INHIBITOR AND A MONOGLYCERIDE | F. HOFFMANN-LA ROCHE AG (CH) | 1996-12-12 | — | — | WO | disclosed |
| EP-0696208-A1 | ORAL DRUG DELIVERY COMPOSITIONS AND METHODS | Emisphere Technologies, Inc. (US) | 1996-02-14 | — | — | EP | disclosed |
| WO-1994023767-A1 | ORAL DRUG DELIVERY COMPOSITIONS AND METHODS | EMISPHERE TECHNOLOGIES, INC. (US) | 1994-10-27 | — | — | WO | disclosed |
| CN-1089606-A | Antiretroviral acyl compounds | CIBA GEIGY AG (CH) | 1994-07-20 | — | — | CN | disclosed |
| EP-0594540-A1 | Antiretroviral acyl compounds | CIBA-GEIGY AG (CH) | 1994-04-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160333049-A1 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | TP53, TP53BP1, MDM2 | ALDH1A1 4043/4885CAPN1 936/4885CTSK 570/4885 |
| US-20170114098-A1 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | NGLY1, BID, DNPEP | ALDH1A1 4647/4885CAPN1 2845/4885CTSK 186/4885 |
| US-20020173469-A1 | Protease inhibitors | CTSK, CTSZ, CTSG | ALDH1A1 3948/4885CAPN1 96/4885CTSK 1/4885 |
| US-20020077455-A1 | Protease inhibitors | CTSK, CTSZ, CTSG | ALDH1A1 3948/4885CAPN1 96/4885CTSK 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.